Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Arvinas lays off 33% of staff, axes Pfizer-partnered trials
Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor degrader R&D plan in the wake of mixed data.
Nick Paul Taylor
May 1, 2025 8:50am
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
Pfizer axes oral GLP-1 asset, blowing hole in obesity plan
Apr 14, 2025 7:34am
Pfizer sells San Diego R&D site for $255M
Apr 10, 2025 11:06am
A closer look at pharma's top R&D budgets
Apr 4, 2025 9:34am
Pfizer, Flagship turn to autoimmune for latest angle of collab
Apr 1, 2025 9:38am
